Repeated superselective intraarterial bevacizumab after blood brain barrier disruption for newly diagnosed glioblastoma: a phase I/II clinical trial.
J Neurooncol
; 155(2): 117-124, 2021 Nov.
Article
in En
| MEDLINE
| ID: mdl-34601657
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Brain Neoplasms
/
Blood-Brain Barrier
/
Glioblastoma
/
Bevacizumab
Type of study:
Diagnostic_studies
/
Guideline
Limits:
Adult
/
Aged
/
Humans
/
Middle aged
Language:
En
Journal:
J Neurooncol
Year:
2021
Type:
Article
Affiliation country:
United States